Memories, like a jigsaw puzzle, are scattered across our minds. Each piece is carefully placed to create an intricate web of memories that make up who we are and how we interact with the world around us.
Exercise and physical therapy play an important role in managing Multiple Sclerosis (MS). Not only can it improve quality of life, but it also has been found to reduce fatigue and improve mobility.
Alzheimer’s disease is a progressive and degenerative disorder that affects an individual’s brain and cognitive functions. It is a type of dementia, a general term for the deterioration of cognitive functions that affects memory, thinking, behavior, and the ability to perform everyday activities.
Multiple Sclerosis is a neurological condition that affects the brain, spinal cord, and optic nerves. While there is no cure for the condition, treatments can help reduce the severity of symptoms and manage the disease.
Exercise and physical therapy play an important role in managing Multiple Sclerosis (MS). Not only can it improve quality of life, but it also has been found to reduce fatigue and improve mobility.
Alzheimer’s disease is a progressive and degenerative disorder that affects an individual’s brain and cognitive functions. It is a type of dementia, a general term for the deterioration of cognitive functions that affects memory, thinking, behavior, and the ability to perform everyday activities.
Dr. Eric Folkens, MD, is a highly qualified family medicine doctor and Pharmaceutical Medical Researcher based in Bradenton, Florida. He has over 22 years of experience in the medical field and is licensed to practice medicine in the state of Florida. Throughout his career, Dr. Folkens has held positions in group practices and worked as …
Accelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with LEQEMBI™ Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials TOKYO and CAMBRIDGE, Mass., Jan. 6, …
TOKYO, Jan. 6, 2023 /PRNewswire/ — LEQEMBI™ (lecanemab-rimb) has the potential to make a difference for people living with early Alzheimer’s disease (AD), their loved ones and healthcare professionals, and was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of AD. Eisai has worked with the FDA and the FDA has approved …
EISAI’S COMMITMENT TO SCIENTIFIC EVIDENCE AND PATIENT Read More »
Multiple Sclerosis is a long-term illness where the body’s immune system attacks and damages the protective covering, called myelin, around the nerves in the central nervous system. People with relapsing MS will have repeated attacks, known as relapses, and we’re finding new ways to stop them. People with MS can experience a variety of symptoms, …
WE’RE FINDING NEW WAYS TO TREAT MULTIPLE SCLEROSIS Read More »
Copyright © 2023 Bradenton Research Center | Website Designed by Rohring Results
